LumiThera Inc. today announced positive findings in its LIGHTSITE III, multi-center clinical trial in non-neovascular (dry) Age-Related Macular Degeneration (AMD) subjects treated with the Valeda® Light Delivery System. The LIGHTSITE III, a prospective, double-masked, randomized, multi-center clinical trial, was conducted at ten leading US retinal centers. The objective was to treat dry AMD subjects with…
eTurboNews Los artículos son sólo para suscriptores. La suscripción es SIN COSTO.
Los suscriptores inician sesión aquí Haga clic aquí para suscribirse GRATIS
Los suscriptores inician sesión aquí Haga clic aquí para suscribirse GRATIS
QUÉ QUITAR DE ESTE ARTÍCULO:
- today announced positive findings in its LIGHTSITE III, multi-center clinical trial in non-neovascular (dry) Age-Related Macular Degeneration (AMD) subjects treated with the Valeda® Light Delivery System.
- The objective was to treat dry AMD subjects with….
- The LIGHTSITE III, a prospective, double-masked, randomized, multi-center clinical trial, was conducted at ten leading US retinal centers.
